Mass SpectrometryTDM Testing ProjectMulti-Psychotropic Drug Panel

Multi-Psychotropic Drug Panel

Abbreviation：KDX / KYY / KJS / KCD / KJLMethod：Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS)

Product Overview
  • Analytes
    Antiepileptic Drugs (8)：Valproic Acid、Oxcarbazepine、Lamotrigine、Levetiracetam、Carbamazepine、Topiramate、Phenytoin、Primidone；
    Antidepressants (21)：Citalopram、Escitalopram、Fluvoxamine、Fluoxetine、Norfluoxetine、Paroxetine、Sertraline、Venlafaxine、O-Desmethylvenlafaxine、Duloxetine、Milnacipran、Agomelatine、Bupropion、Hydroxybupropion、Trazodone、Mirtazapine、Amitriptyline、Imipramine、Doxepin、N-Desmethyl Escitalopram、Clomipramine；
    Antipsychotics (21)：Olanzapine、N-Desmethyl Olanzapine、Clozapine、N-Desmethyl Clozapine、Risperidone、9-Hydroxyrisperidone 、Aripiprazole、Dehydroaripiprazole、Quetiapine、Norquetiapine、Chlorpromazine、Amisulpride、Ziprasidone、Sulpiride、Perphenazine、 Haloperidol、Fluphenazine、Blonanserin、Perospirone、Lurasidone、Thioridazine；
    Anti-dementia Drugs (3)：Donepezil、Memantine、Rivastigmine；
    Anxiolytic (1):Buspirone.
  • Example Clinical Applications
    Therapeutic drug monitoring for medications used in epilepsy, psychiatric disorders, depression, dementia, anxiety disorders, and other neurological diseases.
  • Sample Type
    Serum or plasma (EDTA plasma)
  • Background

    Antipsychotic drugs are primarily used to treat psychiatric disorders such as schizophrenia and bipolar disorder by modulating dopamine receptor activity to alleviate symptoms including hallucinations and delusions. First-generation agents, such as chlorpromazine, exert their effects mainly through dopamine D2 receptor blockade but are associated with a higher incidence of extrapyramidal side effects. Second-generation agents, including olanzapine, quetiapine, and aripiprazole, regulate both dopamine and serotonin receptors, offering improved tolerability while also providing mood-stabilizing and adjunctive antidepressant effects.

    Antiepileptic drugs control seizures by suppressing abnormal neuronal firing, and some also possess mood-stabilizing properties. For example, lamotrigine reduces seizures by inhibiting sodium channels and glutamate release and is also indicated for bipolar depression. Valproic acid enhances GABA-mediated inhibitory neurotransmission but may be associated with metabolic adverse effects.

    Antidepressants improve depressive symptoms by modulating monoamine neurotransmitters such as serotonin and norepinephrine. Selective serotonin reuptake inhibitors (SSRIs), including fluoxetine and sertraline, selectively inhibit serotonin reuptake and generally have fewer adverse effects than tricyclic antidepressants such as amitriptyline. Serotonin–norepinephrine reuptake inhibitors (SNRIs), including venlafaxine, enhance both serotonin and norepinephrine activity and are commonly used for treatment-resistant depression.

    Anti-dementia drugs are primarily indicated for neurodegenerative disorders such as Alzheimer's disease. Cholinesterase inhibitors, such as donepezil, increase acetylcholine levels in the brain, while NMDA receptor antagonists, such as memantine, reduce glutamate-mediated excitotoxicity to help slow cognitive decline.

    These four categories of drugs act on different key targets within the nervous system and differ in their indications and adverse effect profiles. Clinical selection should be individualized according to disease type, patient tolerance, and metabolic risk.

  • Packing Specification
    a5273-1743669577544.png